Searching for synthetic lethality in cancer.
暂无分享,去创建一个
Alan Ashworth | A. Ashworth | C. Lord | J. Frankum | Christopher J Lord | R. Brough | Sara Costa-Cabral | Rachel Brough | Jessica R Frankum | Sara Costa-Cabral
[1] Yiyu Dong,et al. Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer. , 2010, Cancer research.
[2] L. Staudt,et al. Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells , 2010, Oncogene.
[3] Gary D Bader,et al. Systematic Genetic Analysis with Ordered Arrays of Yeast Deletion Mutants , 2001, Science.
[4] A. Tutt,et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.
[5] B. Garvik,et al. Principles for the buffering of genetic variation. , 2001 .
[6] Ronald W. Davis,et al. Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. , 1999, Science.
[7] Nir Hacohen,et al. Minimizing the risk of reporting false positives in large-scale RNAi screens , 2006, Nature Methods.
[8] A. Ashworth,et al. A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. , 2008, DNA repair.
[9] A. Ashworth,et al. DNA Polymerases as Potential Therapeutic Targets for Cancers Deficient in the DNA Mismatch Repair Proteins MSH2 or MLH1 , 2010, Cancer cell.
[10] Rafael A Irizarry,et al. Global synthetic-lethality analysis and yeast functional profiling. , 2006, Trends in genetics : TIG.
[11] L. Hartwell,et al. Differential toxicities of anticancer agents among DNA repair and checkpoint mutants of Saccharomyces cerevisiae. , 2000, Cancer research.
[12] Alan Ashworth,et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.
[13] A. Ashworth,et al. Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. , 2008, Cancer cell.
[14] J. Boeke,et al. DNA helicase gene interaction network defined using synthetic lethality analyzed by microarray , 2003, Nature Genetics.
[15] A. Sturtevant,et al. A Highly Specific Complementary Lethal System in Drosophila Melanogaster. , 1956, Genetics.
[16] A. Ashworth,et al. Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2 , 2009, EMBO molecular medicine.
[17] William A Weiss,et al. Recognizing and exploiting differences between RNAi and small-molecule inhibitors. , 2007, Nature chemical biology.
[18] Elizabeth Iorns,et al. Integrated Functional, Gene Expression and Genomic Analysis for the Identification of Cancer Targets , 2009, PloS one.
[19] Sridhar Ramaswamy,et al. Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells , 2009, Cell.
[20] Nevan J Krogan,et al. High-throughput genetic interaction mapping in the fission yeast Schizosaccharomyces pombe , 2007, Nature Methods.
[21] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[22] Jung-Sik Kim,et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors , 2009, EMBO molecular medicine.
[23] René Bernards,et al. shRNA libraries and their use in cancer genetics , 2006, Nature Methods.
[24] A. Fraser,et al. Systematic mapping of genetic interactions in Caenorhabditis elegans identifies common modifiers of diverse signaling pathways , 2006, Nature Genetics.
[25] J. Lucchesi. Synthetic lethality and semi-lethality among functionally related mutants of Drosophila melanfgaster. , 1968, Genetics.
[26] T. Dobzhansky,et al. Genetics of Natural Populations. Xiii. Recombination and Variability in Populations of Drosophila Pseudoobscura. , 1946, Genetics.
[27] Y. Dong,et al. Systematic functional analysis of the Caenorhabditis elegans genome using RNAi , 2003, Nature.
[28] Alan Ashworth,et al. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Elizabeth Iorns,et al. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor , 2008, The EMBO journal.
[30] Ricky A. Sharma,et al. Molecular and Cellular Pathobiology Cancer Research Poly ( ADP-Ribose ) Polymerase Is Hyperactivated in Homologous Recombination – Defective Cells , 2010 .
[31] A. Ashworth,et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.
[32] Ben S. Wittner,et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.
[33] Brian D. Peyser,et al. Gene function prediction from congruent synthetic lethal interactions in yeast , 2005, Molecular systems biology.
[34] Mark Robson,et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2010, The Lancet.
[35] Y. Oron,et al. Genetic synthetic lethality screen at the single gene level in cultured human cells. , 2001, Nucleic acids research.
[36] A. Ashworth,et al. Utilizing RNA interference to enhance cancer drug discovery , 2007, Nature Reviews Drug Discovery.
[37] A. Ashworth,et al. Biology-driven cancer drug development: back to the future , 2010, BMC Biology.
[38] S. Haggarty,et al. High-throughput screening of small molecules in miniaturized mammalian cell-based assays involving post-translational modifications. , 1999, Chemistry & biology.
[39] Joshua M. Stuart,et al. A global analysis of genetic interactions in Caenorhabditis elegans , 2007, Journal of biology.
[40] Sean R. Collins,et al. A tool-kit for high-throughput, quantitative analyses of genetic interactions in E. coli , 2008, Nature Methods.
[41] Michael J. Emanuele,et al. A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene , 2009, Cell.
[42] S. Wright. DOBZHANSKY'S GENETICS OF NATURAL POPULATIONS , 1982 .
[43] W. Kaelin. The Concept of Synthetic Lethality in the Context of Anticancer Therapy , 2005, Nature Reviews Cancer.
[44] Thomas Helleday,et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.
[45] Elizabeth Iorns,et al. Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization. , 2009, The Biochemical journal.
[46] Ronald W. Davis,et al. Functional profiling of the Saccharomyces cerevisiae genome , 2002, Nature.
[47] L. Hartwell,et al. Integrating genetic approaches into the discovery of anticancer drugs. , 1997, Science.
[48] Gary D Bader,et al. Global Mapping of the Yeast Genetic Interaction Network , 2004, Science.